Tricalcium phosphate nanoparticles are of interest to many biomedical applications because of their good biocompatibility and bioactivity. Hydroxyapatite (HA) has been utilized as implant coatings and bone substitutes. Amorphous calcium phosphate (ACP) are employed as remineralization agents both in-situ and in tooth restorative materials. It is utilized either as components or formed as products of calcium phosphate bone cement.

Tricalcium phosphate-based ceramics found to be attractive materials for orthopedic applications. Tricalcium phosphate nanoparticles due to their bioactivity and biocompatibility. It can also be used for encapsulating antibiotics. Calcium Phosphate Nanoparticles cause very little inflammation to human muscles as compare to other nanoparticles utilized in the drug delivery system.

Tricalcium phosphate nanoparticles, they will be protected from the outer environment and prevented from undesired release to normal tissues or cells during circulation; after accumulating in solid tumor tissue and internalizing into tumor cells, these agents are finally released in endosomes or lysosomes. Therefore, calcium phosphate nanoparticles (CPNPs) have been supposed one of the most promising delivery devices for cancer diagnosis or therapy.

Tricalcium phosphate nanostructures (AMCPs), which trap macromolecules, for instance, antigens and bacterial peptidoglycan, and transport them to the immune cells of the intestinal tissue. Tricalcium phosphate nanoparticles as carriers of therapeutic and imaging agents have recently raised great interest in nanomedicine. CaPs nanoparticles, as well as other kinds of nanoparticles, can be engineered to specifically target the site of the disease (cells or organs), thus minimizing their dispersion in the body and undesired organism-nanoparticles interactions. The most promising and efficient approach to improve their specificity is the “active targeting”, where nanoparticles are conjugated with a targeting moiety able to recognize and bind with high efficacy and selectivity to receptors that are highly expressed only in the therapeutic site.